Clinical utility of serum S100 in the therapy monitoring of patients with high risk malignant melanoma.

被引：0

作者：

Molina, R. ^{[1
]}

Auge, J. M. ^{[1
]}

Domingo, J. ^{[1
]}

Puig, S. ^{[1
]}

Filella, X. ^{[1
]}

Malvehy, J. ^{[1
]}

Castel, T. ^{[1
]}

机构：

[1] T Castel Biochem & Genet Hosp Clin, IDIBAPS, Barcelona, Spain

来源：

TUMOR BIOLOGY | 2006年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[21] Ultraviolet B exposure could influence the interpretation of serum S100β levels in patients with malignant melanoma [J].

Vitzthum, J. ;

Doerr, H. D. ;

Meineke, V. .

BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (04) :772-773

[22] S 100 B: a prognostic marker in malignant melanoma. [J].

Hansson, LO ;

Djuren, E ;

Dijlai-Merzog, R ;

Nilsson, B ;

Hansson, J .

CLINICAL CHEMISTRY, 1998, 44 :A46-A47

[23] Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma [J].

Tas, F ;

Yasasever, V ;

Duranyildiz, D ;

Camlica, H ;

Ustuner, Z ;

Aydiner, A ;

Topuz, E .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (03) :225-228

[24] Serum S100 protein in the follow-up of melanoma patients [J].

Sevila, A ;

Ortiz, B ;

Botella, R ;

Nagore, E ;

Sanmartín, O ;

Maiquez, J ;

Guillén, C .

SKIN AND ENVIRONMENT - PERCEPTION AND PROTECTION, VOLS 1 AND 2, 2001, :675-678

[25] Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma [J].

Acland, K ;

Evans, AV ;

Abraha, H ;

Healy, CMJ ;

Roblin, P ;

Calonje, E ;

Orchard, G ;

Higgins, E ;

Sherwood, R ;

Russell-Jones, R .

BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (05) :832-835

[26] Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma [J].

Jury, CS ;

McAllister, EJ ;

MacKie, RM .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (03) :556-556

[27] Decreases in serum levels of S100 may predict response to therapy in melanoma patients treated with a polyvalent melanoma vaccine [J].

Bar, A ;

Amin, P ;

Reynolds, S ;

Shapiro, R ;

Roses, D ;

Harris, M ;

Bystryn, J .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) :540-540

[28] Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma [J].

Jury, CS ;

McAllister, EJ ;

MacKie, RM .

BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (02) :269-274

[29] The utility of S-100 protein immunostain in evaluating residual tumor and adequacy in desmoplastic malignant melanoma. [J].

Bulatao, I ;

Loy, T ;

Hurly, J .

LABORATORY INVESTIGATION, 1996, 74 (01) :218-218

[30] Serum S100 level is predictive of recurrence-free survival in patients with intermediate risk melanoma [J].